FGFRs are involved in multiple myeloma, in myeloproliferative disorder, and, importantly, in B-cell precursor (BCP) ALL, the latter including the MLL-rearranged leukemias, thereby supporting their crucial role in hematologic malignancies [40,41,42]. The gene discussed is KMT2A; the disease is plasma cell myeloma.